menu
    • menu
    [{"orgOrder":0,"company":"Shenyang Sunshine Pharmaceutical Co Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CHINA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Darbepoetin alfa","moa":"Erythropoietin receptor","graph1":"Nephrology","graph2":"Phase III","graph3":"Shenyang Sunshine Pharmaceutical Co Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shenyang Sunshine Pharmaceutical Co Ltd \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Shenyang Sunshine Pharmaceutical Co Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Nanogen Pharmaceutical Biotechnology","sponsor":"Vietstar Biomedical Research | Medphase Clinical Research Consultant Company Ltd | Clinical Research Viet Nam Skill Training And Consulting | MedProve","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"VIETNAM","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Darbepoetin alfa","moa":"Erythropoietin receptor","graph1":"Hematology","graph2":"Phase III","graph3":"Nanogen Pharmaceutical Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nanogen Pharmaceutical Biotechnology \/ Vietstar Biomedical Research | Medphase Clinical Research Consultant Company Ltd | Clinical Research Viet Nam Skill Training And Consulting | MedProve","highestDevelopmentStatusID":"10","companyTruncated":"Nanogen Pharmaceutical Biotechnology \/ Vietstar Biomedical Research | Medphase Clinical Research Consultant Company Ltd | Clinical Research Viet Nam Skill Training And Consulting | MedProve"},{"orgOrder":0,"company":"Nanogen Pharmaceutical Biotechnology","sponsor":"Vietstar Biomedical Research | Clinical Research Consultants, Inc. | Clinical Research Viet Nam Skill Training And Consulting","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"VIETNAM","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Darbepoetin alfa","moa":"Erythropoietin receptor","graph1":"Nephrology","graph2":"Phase I","graph3":"Nanogen Pharmaceutical Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nanogen Pharmaceutical Biotechnology \/ Vietstar Biomedical Research | Clinical Research Consultants, Inc. | Clinical Research Viet Nam Skill Training And Consulting","highestDevelopmentStatusID":"6","companyTruncated":"Nanogen Pharmaceutical Biotechnology \/ Vietstar Biomedical Research | Clinical Research Consultants, Inc. | Clinical Research Viet Nam Skill Training And Consulting"}]

    Find Clinical Drug Pipeline Developments & Deals for Darbepoetin alfa

    Menu

    Darbepoetin alfa

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Nanogen Pharmaceutical Biotechnology

                            Vietnam arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Nanogen Pharmaceutical Biotechnology

                            Vietnam arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Darbepoetin alfa

                            Therapeutic Area : Nephrology

                            Study Phase : Phase I

                            Sponsor : Vietstar Biomedical Research | Clinical Research Consultants, Inc. | Clinical Research Viet Nam Skill Training And Consulting

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pharmacokinetic/Pharmacodynamic Parameters of NNG-DEPO (Stimus) With Aranesp® (Amgen) in Treatment of Anemi...

                            Details : Darbepoetin Alfa is a Protein drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Renal Insufficiency, Chronic.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            December 05, 2022

                            Lead Product(s) : Darbepoetin alfa

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase I

                            Sponsor : Vietstar Biomedical Research | Clinical Research Consultants, Inc. | Clinical Research Viet Nam Skill Training And Consulting

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Nanogen Pharmaceutical Biotechnology

                            Vietnam arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Nanogen Pharmaceutical Biotechnology

                            Vietnam arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Darbepoetin alfa

                            Therapeutic Area : Hematology

                            Study Phase : Phase III

                            Sponsor : Vietstar Biomedical Research | Medphase Clinical Research Consultant Company Ltd | Clinical Research Viet Nam Skill Training And Consulting | MedProve

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Compare Efficacy and Safety of Nanogen's Darbepoetin Alfa With Aranesp® (Amgen) in the Treatment...

                            Details : NNG-DEPO (Darbepoetin Alfa) is a Protein drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Anemia.

                            Product Name : NNG-DEPO

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            October 19, 2022

                            Lead Product(s) : Darbepoetin alfa

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase III

                            Sponsor : Vietstar Biomedical Research | Medphase Clinical Research Consultant Company Ltd | Clinical Research Viet Nam Skill Training And Consulting | MedProve

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Shenyang Sunshine Pharmaceutical Co Ltd

                            China arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Shenyang Sunshine Pharmaceutical Co Ltd

                            China arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Darbepoetin alfa

                            Therapeutic Area : Nephrology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase III Clinical Study of Recombinant Erythropoiesis Stimulating Protein Injection (rESP) in the Treatment o...

                            Details : Darbepoetin Alfa is a Protein drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Kidney Failure, Chronic.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            January 27, 2022

                            Lead Product(s) : Darbepoetin alfa

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth